Stereotactic body radiotherapy for prostate cancer: Current results of a phase II trial

Frontiers of Radiation Therapy and Oncology

Volumn 43, Issue , 2011, Pages 428-437

  King, Christopher ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CYBERKNIFE; CYSTOSCOPY; DISEASE SEVERITY; DYSURIA; GLEASON SCORE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RECTUM INJURY; SEXUAL FUNCTION; STEREOTACTIC BODY RADIATION THERAPY; TESTIS; TREATMENT PLANNING; TREATMENT RESPONSE; URETHRA STRICTURE;

HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOSURGERY; SURGERY, COMPUTER-ASSISTED; TREATMENT OUTCOME;

ANTIGENS; HOSPITAL DATA PROCESSING; RADIOTHERAPY; UROLOGY;

ANDROGEN DEPRIVATION THERAPY; CONVENTIONAL FRACTIONATIONS; HYPOFRACTIONATION; PLANNING TARGET VOLUMES; PROSTATE SPECIFIC ANTIGEN; QUALITY OF LIFE OUTCOMES; STEREOTACTIC BODY RADIOTHERAPY; TRANSURETHRAL RESECTIONS;

DISEASES;

EID: 79958236574     PISSN: 00719676     EISSN: 16623789     Source Type: Book Series    
DOI: 10.1159/000322507     Document Type: Article

References (10)

1. Hall EJ: Radiobiology for the Radiologist, ed 4. Philadelphia, J.B. Lippincott Company, 1994.
2. Brenner DJ, Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma (comment). Int J Radiat Oncol Biol Phys 1999; 43: 1095-1101. (Pubitemid 29144800)
3. King CR, Fowler JF: A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low (comment). Int J Radiat Oncol Biol Phys 2001; 51: 213-214. (Pubitemid 32758881)
4. Fowler JF, Chappell R, Ritter M: Is alpha/beta for prostate tumors really low? (comment). Int J Radiat Oncol Biol Phys 2001; 50: 1021-1031. (Pubitemid 32594841)
5. Brenner DJ, et al: Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue (comment). Int J Radiat Oncol Biol Phys 2002; 52: 6-13. (Pubitemid 34041562)
6. Lloyd-Davis RW, Collins CD, Swan AV: Carcinoma of prostate treated by a radical external beam radiotherapy using hypofractionation: 22 years experience (1962-1984). Urology 1990; 36: 107-111. (Pubitemid 20239018)
7. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC: Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009; 73: 1043-1048.
8. King CR, Lo A, Kapp DS: Testicular dose from prostate cyberknife: A cautionary note. Int J Radiat Oncol Biol Phys 2009; 73: 636-637.
9. Kuban DA, Tucker SL, Dong L, et al: Long-term results of the M.D. Anderson randomized doseescalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 67-74. (Pubitemid 350251041)
10. Wiegner EA, King CR: Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 2010; 78: 442-448.